fridays microdosing glp 1 Designed to promote daily balance and overall wellness, may offer a lighter, more sustainable way to support areas like: 🌿 Energy 🌿 Focus 🌿 Muscle health 🌿 Sleep quality 🌿 Recovery Say goodbye to providers with

Innovative diagnostic technologies: navigating regulatory frameworks through advances, challenges, and future prospects

Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks

Banerjee K, Banerjee S, Mandal M

Pinch a fold of skin, insert at 45 to 90 degrees, inject slowly, hold for 5 to 10 seconds, then withdraw